Interferon Gamma Released Assay (IGRA) Segment is Expected to be Fastest Growing Segment During Forecast Period for SAM Region  

According to a new market research study on “SAM Latent TB Detection Market to 2027 – COVID-19 Impact and Regional Analysis and Forecast by Test and End User” is expected to reach US$ 133.10 million by 2027 from US$ 99.15 million in 2020. The market is estimated to grow at a CAGR of 4.3% from 2020 to 2027. The report provides trends prevailing in the SAM latent TB detection market along with the drivers and restraints pertaining to the market growth. Increasing prevalence of tuberculosis and growth of market in emerging economies are the major factor driving the growth of the SAM latent TB detection market. However, presence of multidrug resistant tuberculosis (MDR-TB) hinders the growth of SAM latent TB detection market.       

In case of COVID-19, SAM is highly affected especially Brazil followed by Argentina and Columbia. The COVID-19 pandemic has become the most significant challenge in the region. The region's situation is deteriorating as a result of economic uncertainty and ongoing conflicts. Several countries, for example, are undergoing violent conflict and are unable to implement any public health measures. However, the recent pandemic is causing havoc in the SAM region's economies. A sudden drop in domestic and external demand for goods and products, and halted production due to labor shortage, are major impacts observed in the region. Additionally, tightened financial condition is also decreasing the economic activities in the region. The COVID-19 pandemic has had enormous health, social, and economic consequences since the beginning of 2020, and it is expected to continue in 2021 and beyond. Even after some of these effects are mitigated or contained, there will be medium- and long-term consequences, including for the tuberculosis epidemic and response.  The pandemic has the potential to reverse progress toward TB targets by the end of 2019. People with tuberculosis in the region, for example, reported significant difficulties in accessing TB services during the pandemic and associated lockdowns. Difficulties in obtaining transportation to access TB care, as well as increased stigma due to the similar symptoms of both respiratory diseases, have complicated TB management.       

The SAM latent TB detection market has been segmented into the test, end user, and country. Based on test, the market has been segmented into tuberculin skin test (TST) and interferon gamma released assay (IGRA). The tuberculin skin test (TST) segment dominated the SAM latent TB detection market in 2019 and interferon gamma released assay (IGRA) segment is expected to be fastest growing during forecast period. Based on end user, the market has been segmented into the hospitals, diagnostic centers, laboratories, and others. The hospitals segment dominated the SAM latent TB detection market in 2019 and same segment is expected to be fastest growing during forecast period. Based on country, the market has been segmented into Brazil, Argentina, and rest of SAM.     

Abbott; ARKRAY, Inc.; BD; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Oxford Immunotec Ltd; QIAGEN; and Serum Institute of India Pvt. Ltd. are among the leading companies in the SAM latent TB detection market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2020, Serum Institute of India Pvt. Ltd. has developed a new test for diagnosing TB (C-Tb). SSI has entered into a partnership with Serum Institute of India Pvt. Ltd. SIIPL be manufacturing and distributing the test and the production will take place at SIIPL’s facilities in Pune, India.                                

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com